Her first biologic—His first flight of the day

HER FIRST BIOLOGIC

HIS FIRST FLIGHT OF THE DAY

Choose the first-line biologic efficacy of ORENCIA® (abatacept) and help your patients with life's important daily achievements1

LEARN MORE

Onset of efficacy in
biologic-naïve patients

Fast onset for biologic-naïve patients

ACR response rates over time from baseline.

SEE THE DATA

A first-line biologic with a unique MOA

A first-line biologic with a unique MOA

ORENCIA works early in the RA inflammatory cascade and inhibits T-cell activation.1,2

SEE HOW ORENCIA IS DIFFERENT
ORENCIA RESOURCES

Access to BMS medications with comprehensive reimbursement support services

SEE MORE »

A collection of resources designed to support you and your office

SEE MORE »

Training and support materials that you can share with your ORENCIA patients

SEE MORE »

ORENCIA® (abatacept) indicated for moderate to severe RA

Selected Important Safety Information

Concomitant Use with TNF Antagonists: Concurrent therapy with ORENCIA® (abatacept) and a biologic DMARD is not recommended. In controlled clinical trials, adult patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections (63%) and serious infections (4.4%) compared to patients treated with only TNF antagonists (43% and 0.8%, respectively), without an important enhancement of efficacy.

FEATURED RESOURCES
MOA
Mechanism of Action

A slide show that illustrates the unique MOA of ORENCIA2

SEE MORE »
Infusion time
Infusing ORENCIA

A video guide to preparing and administering an infusion of ORENCIA

SEE MORE »
ORENCIA Copay Card
ORENCIA Copay Card

To activate or obtain an ORENCIA self-injection Copay Card

CLICK HERE »

References:

  1. ORENCIA (abatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb.
  2. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114‐1123.
CONTACT

Contact BMS Access and Support
Monday through Friday
8 am to 8 pm EST
1-800-861-0048
www.bmsaccesssupport.com

Register
For the latest from Bristol-Myers Squibb
 
Sign-up here »

You are leaving this site.

You are now leaving www.ORENCIA.com/hcp. This site may provide links or references to other Web sites not affiliated with Bristol-Myers Squibb. Bristol-Myers Squibb is not responsible for the content of such other sites and shall not be liable for any damages or injury arising from users' access to such sites. Links to other sites are provided only as a convenience to users of our site.

You are now leaving www.ORENCIA.com/hcp. You are being redirected to another Bristol-Myers Squibb site.

Would you like to leave this site?

YES
NO

Please verify that you are a US Healthcare Professional

This information is intended for US Healthcare Professionals

Hold your phone upright to continue browsing orencia.com/hcp